Fluticasone furoate restores leptin/leptin receptor pathway in nasal epithelial cells Source: Annual Congress 2011 - Lung cell biology Year: 2011
Leptomycin B (LMB) promotes nuclear retention of fluticasone furoate (FF)-activated glucocorticoid receptor (GR) Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), demonstrates once-daily (OD) efficacy in asthma when dosed in the evening Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF): Prolonged duration of action compared with other ICS Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Formoterol enhances glucocorticoid receptor nuclear translocation in steroid-insensitive severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 250s Year: 2004
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Lack of glucocorticoid receptor activation by formoterol and salmeterol in human bronchial epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 454s Year: 2003
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF), a once-daily inhaled corticosteroid (ICS), demonstrates dose-response efficacy in patients symptomatic on non-steroidal asthma therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2 -agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Inhibitory activity of mometasone furoate and dexamethasone on Mac-1 expression and locomotion of eosinophils from asthmatics subjects Source: Eur Respir J 2002; 20: Suppl. 38, 382s Year: 2002
Formoterol but not salmeterol enhances cytokine release Source: Eur Respir J 2002; 20: Suppl. 38, 619s Year: 2002
The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Activated protein phosphatase PP2A by formoterol enhances nuclear translocation of glucocorticoid receptor induced by budesonide Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004